Acabrunat 100 mg (Acalabrutinib)

Active IngredientAcalabrutinib
Indication:Blood Cancer
Manufacturer:Natco Pharma Ltd.
Packaging30 capsules in 1 bottle
Strength100mg
Delivery Time6 To 15 days
Pack Size: Price Add to Cart
30 Tablets - USD $8.00 Per pill$240.00
View Cart
60 Tablets - USD $7.20 Per pill$432.00
View Cart
90 Tablets - USD $6.48 Per pill$583.20
View Cart

Acabrunat 100 mg (Acalabrutinib)

Description:
Acabrunat 100 mg contains Acalabrutinib, a targeted anticancer medicine known as a Bruton’s tyrosine kinase (BTK) inhibitor. It is used in the treatment of certain blood cancers, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). Acalabrutinib works by blocking BTK, a protein that helps cancer cells grow, reducing their survival and spread.


Key Details:
Strength: 100 mg per capsule
Form: Oral capsules
Indications:

  • Mantle cell lymphoma (MCL)

  • Chronic lymphocytic leukemia (CLL)

  • Small lymphocytic lymphoma (SLL)

Mechanism of Action:
Inhibits BTK, disrupting B-cell receptor signaling and preventing cancer cell proliferation.


Usage Instructions:

  • Take as prescribed by your doctor, typically 100 mg twice daily.

  • Swallow capsules whole with water; do not open, break, or chew.

  • Can be taken with or without food.


Common Side Effects:

  • Headache

  • Diarrhea

  • Fatigue

  • Muscle pain

  • Bruising or bleeding

Serious Warnings (seek medical help):

  • Serious infections (fever, chills)

  • Bleeding problems

  • Irregular heartbeat (atrial fibrillation)

  • High blood pressure


Important Notes:

  • Regular blood tests are required to monitor your condition.

  • Inform your doctor about all other medications, including blood thinners or antiplatelet drugs.

  • Avoid grapefruit and Seville oranges, as they can affect drug levels.

Pack Size:

30 Tablets – USD $8.00 Per pill, 60 Tablets – USD $7.20 Per pill, 90 Tablets – USD $6.48 Per pill

There are no reviews yet.

Be the first to review “Acabrunat 100 mg (Acalabrutinib)”